Join the Iowa Biotechnology Association

The Iowa Biotechnology Association (IBA) was formed in 1994 to advance opportunities in Iowa for the improvement of the human environmental and economic well-being through the development and application of value-added technologies in the life sciences.

Working cooperatively, the members hope to enhance the ability to commercialize new technologies in a timely manner and reduce the lead time for deployment. Activities of the association are designed to give companies doing business in Iowa an edge in delivering timely new products to consumers through the sharing of ideas regarding the transfer and development of technologies.

Learn About Iowa's BioHistory

Through Iowa BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of Iowa.

Local News...

Free News Release Posting & Archiving Service


• Stereotaxis' market leadership highlighted at Heart Rhythm 2008  Stereotaxis announced that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation.
  Stereotaxis, Inc.  May 09, 2008  
  
  
• Spectrum announces sale of injectable generic drugs to Sagent  Spectrum Pharmaceuticals announced that it has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
  Spectrum Pharmaceuticals, Inc.  May 09, 2008  
  
  
• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• Invitrogen and WARF sign license agreement for human embryonic stem cells  Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
  Invitrogen Corporation  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: TechMatch
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/13/2008: 7th Annual Medtech Investing Conference

More... | Submit Event | Event Advertising...